Bruker Corporation. (5/23/10). "Press Release: Bruker Features New High Performance Mass Spectrometry Systems and Applications for the Detailed Analysis of Biotherapeutics at ASMS". Salt Lake City, UT.

	Region	Salt Lake City, UT
	Country	United States (USA)
	Organisation	Bruker Daltonics (Operating Business of Bruker Corporation)
	Group	Bruker Corporation (Group)
	Organisation 2	ASMS (American Society for Mass Spectrometry)
	Product	autoflex™ speed MALDI-TOF(/TOF) with 1kHz Smartbeam™-II laser
	Product 2	biopharmaceutical
	Person	Seymour, Clive (Bruker Daltonics 200812 Executive VP before probably Biacore)
	Person 2	Asa, Darwin (Waters 201201– Senior Product Marketing Manager Clinical before Bruker Corp + ESA + Tecan)

A range of Bruker MALDI-TOF and LCMS based systems are designed for the comprehensive analysis of Biotherapeutics. These powerful systems provide researchers with unique capabilities that deliver unprecedented levels of information for the development of a Biotherapeutic.

At the 58th ASMS conference, Bruker unveils a series of new products and application solutions targeted to improve the capabilities of researchers to develop biotherapeutics. As many biotherapeutics currently under development are protein or peptide based, Bruker has applied its extensive expertise in protein analysis to develop solutions for many common tasks in analyzing a protein or peptide based biotherapeutic including:

* Analysis of Truncations and Splice Variants
* Identification of Point Mutations
* Identification of Fusion Proteins
* Protein Glycoform Analysis
* Glycan Structure Identification
* PEGylation Analysis

At ASMS, Bruker will feature systems and applications built on the class leading Flex(TM) series of MALDI mass spectrometers for direct N- and C-terminal protein sequence analysis utilizing Bruker's innovative top-down Edmass(TM) protein sequencing technology. This technique is often able to read dozens of amino acids from the important terminal residues of a protein, regardless of any protein modifications, and is superior in many aspects to traditional Edman sequencing. This application area is further enhanced by the launch of the new faster, highly efficient autoflex speed(TM) at ASMS designed to increase the productivity and capabilities of development operations.

In addition to the proven micrO-TOF(TM) and micrO-TOF-QII(TM)benchtop LCMS ESI-TOF systems, Bruker has applied its maXis(TM) UHR-TOF and amaZon ETD(TM) ion trap systems for the analysis of intact proteins and post translational modifications (PTMs). Several key technical presentations will highlight the powerful and unique capabilities of these systems to provide important information for the analysis of potential biotherapeutics. Utilization of the superior resolution (at least 40,000) and mass accuracy (<1 ppm) of the maXis allows for quick, detailed direct analysis of intact proteins of masses up to, and including, monoclonal antibodies. As a further enhancement to its capabilities, the maXis is the only high resolution, high performance MS system fully capable of integration with UHPLC without any comprise in performance. The amaZon ETD can use gentle Electron Transfer Dissociation (ETD) fragmentation methods to quickly and accurately identify and analyze PTMs from biotherapeutics. The amaZon ETD possesses superior sensitivity and speed and can give detailed information about the site of protein modification, and utilize MSn to generate detailed structural information about complex glycans. At ASMS, Bruker will also introduce a revolutionary large protein ETD capability for the maXis platform.

Dr. Clive Seymour, Executive Vice President at Bruker Daltonics, commented: "The combination of new products and extensive application of our mass spectrometry technologies to the analysis of biotherapeutics couldn't have come at a better time. With the current emphasis in many pharmaceutical and biotech companies on the development of biotherapeutics, the need for better, more efficient tools to analyze these complicated molecules has become acute. We've utilized our extensive expertise in protein analytics to create some of the best, most innovative solutions for driving the development of a biotherapeutic in both discovery and development laboratories."

Many of the products for analyzing biotherapeutics will be highlighted by researchers from various pharmaceutical companies at Bruker's Users Meeting on Sunday, May 23rd, 2010 before the 58th ASMS Conference on Mass Spectrometry in Salt Lake City, Utah (USA). For more information on Bruker's User Meeting and other ASMS activities, please visit www.bdal.com/asms2010.

For More Information:

For more information on solutions for analyzing biotherapeutics, please visit www.bdal.com

For information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com

Bruker Daltonics
Darwin Asa, Ph.D.,
+1 (978) 663-3660, ext. 1149
Life-Science Marketing Manager,
dja@bdal.com

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

Bruker Corporation. (5/23/10). "Press Release: Bruker Features New High Performance Mass Spectrometry Systems and Applications for the Detailed Analysis of Biotherapeutics at ASMS". Salt Lake City, UT.

More documents for Bruker Corporation (Group)